Press-release for stocks related to iot

Prices are updated after-hours

approved tags : Iot

save search

Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Published: 2022-03-16 (Crawled : 12:00) - biospace.com/
SONN | $1.7 -6.47% 17K

Health Technology

| 541.77% | O: 79.48% H: 35.23% C: 4.04%
son-1010 treatment fda clearance solid tumors therapeutics fda clearance iot

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -9.93% | O: -3.03% H: 3.21% C: 3.21%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -8.82% | O: 3.07% H: 0.0% C: 0.0%
thio-101 phase 2 technology trial approval australia biotech iot

Trinity Biotech Announces the World Health Organistion Approval Of TrinScreen™ HIV
Published: 2022-02-14 (Crawled : 14:30) - trinitybiotech.com
TRIB | $1.83 -0.54% -0.55% 23K

Health Technology

| 60.0% | O: 3.48% H: 0.84% C: -6.72%
health approval biotech iot hiv

Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
Published: 2022-02-14 (Crawled : 13:30) - globenewswire.com
TRIB | $1.83 -0.54% -0.55% 23K

Health Technology

| 60.0% | O: 3.48% H: 0.84% C: -6.72%
health approval biotech iot hiv

Trinity Biotech Announces That Its Shareholders Have Approved All of the Four Resolutions That Were the Subject of the EGM Held on January 25, 2022
Published: 2022-01-25 (Crawled : 14:00) - biospace.com/
TRIB | $1.83 -0.54% -0.55% 23K

Health Technology

| 60.0% | O: 8.7% H: 0.0% C: -4.8%
ces biotech iot

Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
Published: 2022-01-13 (Crawled : 13:30) - biospace.com/
EDSA | $4.4 -2.3% 1.4K

Health Technology

| -22.42% | O: 6.49% H: 0.0% C: -13.11%
covid-19 drug approval covid test therapy biotech iot

Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
ADVM | $11.135 -1.89% -1.93% 100K

Health Technology

| 495.38% | O: -1.54% H: 1.04% C: -5.73%
treatment fda gene therapy drug granted preclinical orphan drug therapy biotech iot pre-clinical designation

FDA Approves XBiotech’s IND in RheumatologyLaunching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
XBIT | $7.9 -2.59% -2.66% 99K

Health Technology

| -30.57% | O: -1.37% H: 0.0% C: 0.0%
fda therapy antibody biotech iot

PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based CombinationInstitutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
PDSB | $2.89 6.25% 5.88% 1.1M

Health Technology

| -65.56% | O: -2.14% H: 0.0% C: 0.0%
phase 2 trial approval cancer biotech iot

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Published: 2021-10-12 (Crawled : 23:00) - cytosorbents.com
CTSO | $0.8011 1.41% 1.39% 100K

Health Technology

| -88.46% | O: -1.3% H: 0.0% C: -10.38%
fda drug device iot cardio trial approval

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis
Published: 2021-09-29 (Crawled : 14:00) - biospace.com/
KRYS | $164.04 -3.3% -3.41% 280K

Health Technology

| 207.6% | O: 1.07% H: 0.25% C: -3.55%
fibrosis phase 1 biotech research iot trial approval cystic fibrosis

Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Published: 2021-08-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -16.6% | O: 0.01% H: 0.85% C: 0.79%
CTSO | $0.8011 1.41% 1.39% 100K

Health Technology

| -89.74% | O: 5.13% H: 2.35% C: -2.44%
fda drug device iot cardio designation

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy
Published: 2021-07-30 (Crawled : 12:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M

Health Technology

| -29.13% | O: 0.0% H: 0.0% C: 0.0%
disease treatment europe therapy cancer iot approval nivolumab

Founder Shield: Navigating Biotech Risks from Discovery to Approval
Published: 2021-07-13 (Crawled : 13:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -14.47% | O: -0.3% H: 0.46% C: 0.18%
risk biotech iot approval

CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
CTSO | $0.8011 1.41% 1.39% 100K

Health Technology

| -89.53% | O: 2.07% H: 12.34% C: 10.67%
fda fda approval device iot cardio trial approval

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
Published: 2021-07-01 (Crawled : 13:00) - biospace.com/
PBYI | $4.98 -3.68% -3.82% 290K

Health Technology

| -43.68% | O: 0.11% H: 3.16% C: 2.18%
fda positive cancer biotech technology iot breast cancer fda approval her2+ her2- her2 metastatic breast cancer